XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
  Diabetes
   Insulin Resistance
   NIDDM
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
Search

Last Updated: Nov 18, 2006 - 1:55:25 PM

NIDDM Channel
subscribe to NIDDM newsletter

Latest Research : Endocrinology : Diabetes : NIDDM

   DISCUSS   |   EMAIL   |   PRINT
Panel Recommends Muraglitazar for the Treatment of Type 2 Diabetes
Sep 10, 2005 - 10:27:00 PM, Reviewed by: Dr.

PARGLUVA is an investigational oral medication that, if approved, would become the first marketed agent in a new class of compounds called glitazars.

 
Bristol-Myers Squibb and Merck & Co., Inc. jointly announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted to recommend approval of PARGLUVA(TM) (muraglitazar), the companies' investigational oral medicine for the treatment of type 2 diabetes, for use as monotherapy and in combination with metformin. The committee voted not to recommend its use in combination with a sulfonylurea.

PARGLUVA is an investigational oral medication that, if approved, would become the first marketed agent in a new class of compounds called glitazars. PARGLUVA is a dual alpha/gamma PPAR (peroxisome proliferator-activated receptor) activator. Activation of PPAR-gamma is associated with reductions in plasma glucose levels, while activation of PPAR-alpha is associated with reductions in plasma triglyceride levels and increases in high-density lipoprotein, or "good" cholesterol (HDL-C) levels.

Bristol-Myers Squibb and Merck are collaborators in the global development and commercialization of PARGLUVA. The New Drug Application (NDA) for PARGLUVA was submitted to the FDA in late December 2004.

"Bristol-Myers Squibb and Merck are encouraged by this recommendation," said Elliott Sigal, M.D., Ph.D., chief scientific officer and president, Pharmaceutical Research Institute, Bristol-Myers Squibb. "We are committed to bringing important medicines to patients with type 2 diabetes and look forward to further discussions with the FDA."
 

- U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee
 

www.bms.com

 
Subscribe to NIDDM Newsletter
E-mail Address:

 

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains certain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 regarding a product in development and the potential efficacy of such product that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainty of the success of the research and development activities; decisions by regulatory authorities regarding whether and when to approve any new drug application for a product candidate that may result from the research, as well as their decisions regarding labeling and other matters that could affect the commercial potential of such product candidate; and competitive developments. A further list and description of risks and uncertainties can be found in the Bristol-Myers Squibb's Annual Report on Form 10-K for the fiscal year ended December 31, 2004, and in its reports on Form 10-Q and Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Merck Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K, which the company incorporates by reference.

CONTACT: Media, David M. Rosen of Bristol-Myers Squibb Company,+1-609-721-6155, ; or Tracy Ogden of Merck & Co.,Inc., +1-484-686-4837, ; or Investors, John Elicker ofBristol- Myers Squibb Company, +1-212-546-3775; or Graeme Bell of Merck &Co., Inc., +1-908-423-5185, [email protected] [email protected] [email protected]


Related NIDDM News
Data support role for adult spleen cells in regeneration of beta cells
Researchers reveal mechanisms behind Thiazolidinediones in type 2 diabetes
High-fat diet supresses GnT-4a activity to cause type 2 diabetes
Low blood glucose levels may complicate gastric bypass surgery
Muraglitazar found to increase adverse cardiovascular events
Insulin's role in blocking release of energy
TORC2 - Key regulator of blood glucose levels discovered
Panel Recommends Muraglitazar for the Treatment of Type 2 Diabetes
Persons at risk for type 2 diabetes have lower rate of cellular energy production
Sirt1 protein enhances the secretion of Insulin


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us